Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer

Table 1 Clinical characteristics of the HER2-positive and HER2-negative patients

	HER2-positive (n = 29)	HER2-negative (n = 40)
Median age at diagnosis	64.5	78
Median age at diagnosis	Range 32–79	Range 40–87
Gender
Male	20 (69%)	22 (55%)
Female	9 (31%)	18 (45%)
Stage at diagnosis
2	3 (10.3%)	2 (5%)
3	5 (17.2%)	9 (22.5)
4	18 (62.1%)	22 (55%)
Unknown	3 (10.3%)	7 (17.5%)
Treatment
None	3 (10.3%)	28 (70%)
Trastuzumab-based	17 (58.6%)	0 (0%)
Chemotherapy alone	9 (31%)	12 (30%)
Tumour location
Stomach	13 (44.8%)	21 (52.5%)
Gastro-oesophageal junction	16 (55.2%)	19 (47.5%)

In the HER2-positive patient cohort trastuzumab was given in combination with oxaliplatin and capecitabine or fluorouracil in 14 patients, and with fluorouracil alone in three patients. In the HER2-negative cohort, seven patients received fluorouracil and leucovorin, one patient received docetaxol and carboplatin, one patient received docetaxol, carboplatin and fluorouracil, one patient received oxaliplatin and fluorouracil and two patients received capecitabine alone

ISSN: 1479-5876